Renascor Resources Limited

RNU

Renascor Resources Ltd. engages in the exploration and evaluation of mineral property. The company is headquartered in Adelaide, South Australia. The company went IPO on 2010-12-15. The Company’s projects include Siviour Battery Anode Materials, Carnding Gold, Marree, Olary and Eastern Eyre. The Carnding Project contains several near-surface, high-grade gold prospects (up to 16 g/t from previous drilling) in South Australia’s Central Gawler Craton. At Carnding, the Company is targeting shallow, high-grade gold occurrences. Within the project area, the Company has identified multiple high priority gold targets based on shallow drilling. The Marree Project is a copper-prospective ground position within South Australia’s Adelaide Fold Belt. Its exploration program is focused on identifying and drilling prospects for large tonnage Zambian Copper Belt-style, sedimentary copper deposits. The company holds interest in Marree Project exploration licenses, EL 6170 and EL 6403.

Biotron Limited

BIT

Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate and applied biotechnology research and development projects. The firm is engaged in developing and commercializing a small molecule approach that has the potential to treat a number of serious viral diseases. Its primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins. BIT225 is its lead antiviral clinical-stage, investigational, small molecule antiviral drug. BIT225 is in Phase II development for the treatment of human immunodeficiency virus-1 (HIV-1) and Hepatitis C virus infections. The company also has commenced a program to develop an antiviral drug to treat SARS-CoV-2 infection. Its BIT225 drug has shown clinical efficacy against SARS-CoV-2 in early-stage research studies. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as Dengue, Zika and Influenza virus.

Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its HER-Vaxx is a B-cell immuno-therapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. PD1-Vaxx is a B-cell immuno-therapy, which aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer. Its clinical trial candidates include VAXINIA, CHECKvacc, B-Vaxx and others. Its platform technologies seek to harness the body’s immune system against tumors.

Vanguard Australian Shares High Yield Etf

VHY

VHY.AX was created on 2011-05-26 by Vanguard. The fund's investment portfolio concentrates primarily on high dividend yield equity. Vanguard Australian Shares High Yield ETF seeks to track the return of the FTSE Australia High Dividend Yield Index before taking into account fees, expenses and tax.